Literature DB >> 18547687

Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori.

Caroline D Skene1, Christopher Doidge, Philip Sutton.   

Abstract

An important obstacle to development of an effective vaccine against Helicobacter pylori is the lack of a suitable adjuvant. This study evaluated the effectiveness of ISCOMATRIX and ISCOM vaccines at inducing protective immunity against H. pylori in mice. Immunisation with ISCOMATRIX and ISCOM vaccines resulted in a reduction in H. pylori colonisation equivalent to that induced by the gold standard cholera toxin (CT) adjuvant. Protection was induced in two mouse backgrounds, using two different bacterial antigens and following vaccine delivery via either the intranasal or subcutaneous route. This supports the potential of ISCOMATRIX and ISCOM technologies in H. pylori vaccine development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547687     DOI: 10.1016/j.vaccine.2008.05.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.

Authors:  Haibo Li; Jinyong Zhang; Yafei He; Bin Li; Li Chen; Weiwei Huang; Quanming Zou; Chao Wu
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

2.  Recombinant herpesvirus glycoprotein G improves the protective immune response to Helicobacter pylori vaccination in a mouse model of disease.

Authors:  Louise Baker; Andre M L Chitas; Carol A Hartley; Mauricio J C Coppo; Paola K Vaz; Andrew Stent; James R Gilkerson; Joanne M Devlin; Alison L Every
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

Review 3.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.